Making the announcement, Krishna Kanumuri, CEO & MD, Sai Life Sciences said, "We are at a very exciting point in our journey and are looking to expand our team of highly-motivated scientists. This will help us better serve our customers by accelerating their projects involving complex chemistry and next-generation technologies."

The current expansion is part of Sai Nxt, an organization-wide initiative aimed at transforming the company into a new generation CDMO, with investments of over US$150 million during the period.

Scheduled to be functional by May 2020, the upcoming R&T facility in genome valley, Hyderabad, will have 83,000 sq. ft. of lab space and house state-of-the-art research capabilities with advanced technology platforms. The facility adds to the company's growing range of capabilities and facilities across drug discovery, development and manufacturing. Over the past few months, Sai Life Sciences has added 172 KL cGMP API & Intermediate manufacturing capacity, opened a Biology Lab in Cambridge, Massachusetts, USA, and is setting up a Process R&D Lab in Manchester, UK. 

The company is looking to on-board top-notch global scientific talent with M.Sc./PhD / Post Doctorates in synthetic organic/analytical chemistry from reputed academic institutions, and experience in global pharma R&D of up to 20 years, for various roles across levels in discovery chemistry, process R&D, analytical R&D as well as in Biology, DMPK, Toxicology among others. The list of open positions are available on the careers page of the website.